Drug Trial Radar · NCT06220214
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Mar 6, 2024
Primary completion
Jul 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Alison StopeckAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 23, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare a special type of mammogram that uses a contrast agent called contrast-enhanced digital mammography with contrast-enhanced digital breast tomosynthesis (CEDM+CEDBT), with breast magnetic resonance imaging imaging (MRI) for predicting the effect of neoadjuvant chemotherapy on pathologic complete response rates. The device used to obtain CEDM+CEDBT images is called Siemens MAMMOMAT. This device produces two-dimensional (2D) images, as in a normal mammogram, but also collects additional images for digital breast tomosynthesis (DBT), which produces a three-dimensional (3D) image of the breast in the form of image slices. DBT allows the radiologist to "see through" the breast tissue for better detection and localization of breast cancer. By looking at both the CEDM images and the CEDBT images, a radiologist may be able to better detect residual breast cancer in a more cost-effective manner. Participation may last up to 18 weeks. Study procedures for this research are: * Undergoing 1-2 mammograms during and/or after your chemotherapy, but before primary breast surgery. * Before each mammogram, have a radiology technician inject a liquid contrast agent by inserting a needle into a vein. The chemotherapy port cannot be used to receive the contrast agent * Let the research team record information from your medical record related to your condition and the treatment you receive. * Give permission to collect leftover tissue from your diagnostic biopsy and breast surgery.
Conditions
- Breast Cancer
- Locally Advanced Breast Cancer
- Neoadjuvant Chemotherapy
- HER2-positive Breast Cancer
- Triple Negative Breast Cancer
- TNBC, Triple Negative Breast Cancer
Interventions
CEDMDiagnostic test
Contrast Enhanced Digital Mammography
CEDBTDiagnostic test
Contrast-Enhanced Digital Breast Tomosynthesis
Omnipaque 350mgI/mL Solution for InjectionDrug
Injection of an FDA approved iodinated contrast agent is required to undergo the imaging procedures. It is not the intent of the study to evaluate the contrast agent, but it will be administered at the time of experimental imaging.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Accuracy of (CEDM+CEDBT) to predict NAC treatment effectsTime frame: Immediately after definitive breast surgery, up to 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stony Brook Breast Center
Stony Brook, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.